Zevra Therapeutics (ZVRA) to Release Earnings on Wednesday

Zevra Therapeutics (NASDAQ:ZVRA) is scheduled to be releasing its earnings data before the market opens on Wednesday, May 8th. Analysts expect the company to announce earnings of ($0.49) per share for the quarter.

Zevra Therapeutics (NASDAQ:ZVRA) last released its earnings results on Thursday, March 28th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.20). Zevra Therapeutics had a negative net margin of 167.69% and a negative return on equity of 68.41%. The business had revenue of $13.22 million for the quarter, compared to the consensus estimate of $13.35 million. On average, analysts expect Zevra Therapeutics to post $-2 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Zevra Therapeutics Stock Performance

Shares of Zevra Therapeutics stock traded up $0.07 during trading hours on Thursday, reaching $4.67. The company’s stock had a trading volume of 11,056 shares, compared to its average volume of 242,352. The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.18 and a current ratio of 1.18. Zevra Therapeutics has a one year low of $3.89 and a one year high of $7.28. The company’s 50 day simple moving average is $5.54 and its 200 day simple moving average is $5.36. The stock has a market cap of $202.82 million, a P/E ratio of -3.82 and a beta of 1.87.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on ZVRA. William Blair restated an “outperform” rating on shares of Zevra Therapeutics in a research note on Tuesday, March 12th. Cantor Fitzgerald restated an “overweight” rating on shares of Zevra Therapeutics in a research note on Monday, April 1st. HC Wainwright reiterated a “buy” rating and issued a $15.00 target price on shares of Zevra Therapeutics in a research note on Wednesday, April 3rd. Finally, Maxim Group upped their price target on shares of Zevra Therapeutics from $12.00 to $18.00 and gave the stock a “buy” rating in a research report on Tuesday, April 2nd. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $19.50.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc, a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications.